These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8310765)

  • 1. Evaluation of the immunogenicity of a recombinant vaccine against hepatitis B containing S and pre-S2 sequences using two different schedules.
    Gizaris V; Roumeliotou A; Ktenas E; Papoutsakis G; Papaevangelou G
    Vaccine; 1993 Nov; 11(14):1445-7. PubMed ID: 8310765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates.
    Yerushalmi B; Raz R; Blondheim O; Shumov E; Koren R; Dagan R
    Pediatr Infect Dis J; 1997 Jun; 16(6):587-92. PubMed ID: 9194109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
    Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
    Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India.
    Hussain Z; Ali SS; Husain SA; Raish M; Sharma DR; Kar P
    World J Gastroenterol; 2005 Dec; 11(45):7165-8. PubMed ID: 16437665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study.
    Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH
    Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 years.
    Moulia-Pelat JP; Spiegel A; Martin PM; Cardines R; Boutin JP; Roux JF; Excler JL; Saliou P
    Vaccine; 1994 May; 12(6):499-502. PubMed ID: 8036822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen.
    Douvin C; Simon D; Charles MA; Deforges L; Bierling P; Lehner V; Budkowska A; Dhumeaux D
    Diabetes Care; 1997 Feb; 20(2):148-51. PubMed ID: 9118762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a 'pre-S2 plus S' hepatitis B vaccine in healthy adults.
    Katkov WN; Watkins E; DeMelia HC; Dienstag JL
    J Viral Hepat; 1994; 1(1):79-83. PubMed ID: 8790563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens.
    Soulié JC; Devillier P; Santarelli J; Goudeau A; Vermeulen P; Guellier M; Saliou P; Hillion AM; Tron F; Huchet J
    Vaccine; 1991 Aug; 9(8):545-8. PubMed ID: 1837646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination.
    Baldy JL; de Lima GZ; Morimoto HK; Reiche EM; Matsuo T; de Mattos ED; Sudan LC
    Rev Inst Med Trop Sao Paulo; 2004; 46(2):103-7. PubMed ID: 15141282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients.
    el-Reshaid K; al-Mufti S; Johny KV; Sugathan TN
    Vaccine; 1994; 12(3):223-34. PubMed ID: 8165854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results.
    Van Herck K; Van Damme P; Thoelen S; Meheus A
    Vaccine; 1998 Dec; 16(20):1933-5. PubMed ID: 9796046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates.
    Bassily S; Kotkat A; Gray G; Hyams KC; Brown FM; Imam IZ; Arthur R
    Am J Trop Med Hyg; 1995 Oct; 53(4):419-22. PubMed ID: 7485697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunogenicity and harmlessness in the newborn of a vaccine (GenHevac B) containing the antigens S and pre-S2].
    Tron F; Soulié JC; Goudeau A; Devillier P; Saliou P
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):901-5. PubMed ID: 1840243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.
    Lu S; Ren J; Li Q; Jiang Z; Chen Y; Xu K; Ruan B; Yang S; Xie T; Yang L; Li J; Yao J
    Hum Vaccin Immunother; 2017 Apr; 13(4):903-908. PubMed ID: 27905821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders.
    Das K; Gupta RK; Kumar V; Kar P
    World J Gastroenterol; 2003 May; 9(5):1132-4. PubMed ID: 12717874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparison of antibody response to different hepatitis b vaccines with and without pre-S2 antigen in children with cancer.
    Emir S; Büyükpamuk M; Akyüz C; Kutluk T; Güler E; Cağlar K
    Pediatr Hematol Oncol; 2002 Jun; 19(4):227-33. PubMed ID: 12051588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children.
    Raz R; Dagan R; Gallil A; Brill G; Kassis I; Koren R
    Vaccine; 1996 Feb; 14(3):207-11. PubMed ID: 8920701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
    Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
    Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China.
    Wang ZZ; Gao YH; Lu W; Jin CD; Zeng Y; Yan L; Ding F; Li T; Liu XE; Zhuang H
    Hum Vaccin Immunother; 2017 Apr; 13(4):909-915. PubMed ID: 27874311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.